<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883737</url>
  </required_header>
  <id_info>
    <org_study_id>PNM and knee</org_study_id>
    <nct_id>NCT03883737</nct_id>
  </id_info>
  <brief_title>Percutaneous Neuromodulation on the Anterior Pain Knee</brief_title>
  <official_title>Effect of the Ultrasound-guided Percutaneous Neuromodulation on the Anterior Pain Knee: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Seville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Seville</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anterior knee pain (AKP) is one of the most frequent pathologies of the lower limb, in young
      and adult subjects. In the field of Physiotherapy, ultrasound-guided Percutaneous
      Neuromodulation (PNM) is defined as the application through a needle with ultrasound guidance
      of an electrical current at low or medium frequency, seeking a sensitive and / or motor
      response of a peripheral nerve in some point of its trajectory, or of a muscle in a motor
      point, with a therapeutic objective. The objective of this study is to analyze that the
      effect of PNM on the femoral nerve produces statistically significant changes in pain, joint
      range and knee functionality in patients with chronic AKP. Thirty subjects will be recruited,
      which will be divided into 2 groups: group 1 to which PNM will be applied to the femoral
      nerve of the pain knee; and group 2 to which PNM will be applied to the femoral nerve of the
      non-pain knee. The PNM intervention with NMP will consist in the single application of an
      asymmetric rectangular biphasic current (250 microseconds, 10 Hz)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2019</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual analog scale (VAS) (0, no pain; 100, maximum pain).</measure>
    <time_frame>up to 1 week</time_frame>
    <description>pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>range joint</measure>
    <time_frame>up to 1 week</time_frame>
    <description>goniometer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VISA-p questionnaire (0, maximum pain; 100, no pain).</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Functional pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kujala questionnaire (0, maximum pain; 100, no pain).</measure>
    <time_frame>up to 1 week</time_frame>
    <description>Functional pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Neuromodulation</condition>
  <condition>Anterior Pain Knee</condition>
  <condition>Femoral Nerve</condition>
  <arm_group>
    <arm_group_label>Group 1: PNM in pain knee</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants in whom PNM will be applied to the femoral nerve of the pain knee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: PNM in non-pain knee</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants in whom PNM will be applied to the femoral nerve of the non-pain knee</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PNM</intervention_name>
    <description>an asymmetric rectangular biphasic current (250 microseconds, 10 Hz)</description>
    <arm_group_label>Group 1: PNM in pain knee</arm_group_label>
    <arm_group_label>Group 2: PNM in non-pain knee</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic anterior knee pain &gt;3 months

          -  older than 18 years-old

        Exclusion Criteria:

          -  Surgical intervention in the intervention area

          -  Prosthesis or osteosynthesis in the intervention area

          -  Cardiac or tumoral diseases

          -  Coagulopathies

          -  Be under the effects of certain medications

          -  contraindication characteristic of the puncture
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Seville</name>
      <address>
        <city>Seville</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.mdpi.com/2076-3417/10/13/4647</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 16, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Seville</investigator_affiliation>
    <investigator_full_name>Blanca de la Cruz Torres</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

